Ching-Shih Chen - Publications

University of Kentucky, Lexington, KY 

111 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2019 Kulp SK, Chen CS, Wang DS, Chen CY, Chen CS. Retraction: Antitumor Effects of a Novel Phenylbutyrate-based Histone Deacetylase Inhibitor, ()-HDAC-42, in Prostate Cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 25: 2940. PMID 31043388 DOI: 10.1158/1078-0432.CCR-19-0731  0.44
2019 Chu PC, Kulp SK, Chen CS. Retraction: Corrigendum: Insulin-like growth factor-I receptor is suppressed through transcriptional repression and mRNA destabilization by a novel energy restriction-mimetic agent. Carcinogenesis. 40: e15. PMID 31034566 DOI: 10.1093/carcin/bgz057  0.44
2019 Lai IL, Chou CC, Lai PT, Fang CS, Shirley LA, Yan R, Mo X, Bloomston M, K Kulp S, Bekaii-Saab T, Chen CS. Retraction: Targeting the Warburg effect with a novel glucose transporter inhibitor to overcome gemcitabine resistance in pancreatic cancer cells. Carcinogenesis. 40: e16. PMID 31034565 DOI: 10.1093/carcin/bgz056  0.44
2019 Chu PC, Kulp SK, Chen CS. Retraction: Insulin-like growth factor-I receptor is suppressed through transcriptional repression and mRNA destabilization by a novel energy restriction-mimetic agent. Carcinogenesis. 40: e14. PMID 31034564 DOI: 10.1093/carcin/bgz055  0.44
2019 Weng SC, Kashida Y, Kulp SK, Wang D, Brueggemeier RW, Shapiro CL, Chen CS. Retraction: Sensitizing Estrogen Receptor-negative Breast Cancer Cells to Tamoxifen with OSU-03012, a Novel Celecoxib-derived Phosphoinositide-dependent Protein Kinase-1/Akt Signaling Inhibitor. Molecular Cancer Therapeutics. 18: 869. PMID 30936413 DOI: 10.1158/1535-7163.MCT-19-0151  0.44
2019 Zhu J, Huang JW, Tseng PH, Yang YT, Fowble J, Shiau CW, Shaw YJ, Kulp SK, Chen CS. Editor's Note: From the Cyclooxygenase-2 Inhibitor Celecoxib to a Novel Class of 3-Phosphoinositide-Dependent Protein Kinase-1 Inhibitors. Cancer Research. 79: 1716. PMID 30936080 DOI: 10.1158/0008-5472.CAN-19-0502  0.44
2018 Wang D, Chu PC, Yang CN, Yan R, Chuang YC, Kulp SK, Chen CS. Retraction of "Development of a Novel Class of Glucose Transporter Inhibitors". Journal of Medicinal Chemistry. PMID 29772905 DOI: 10.1021/acs.jmedchem.8b00708  0.44
2018 Guh JH, Chang WL, Yang J, Lee SL, Wei S, Wang D, Kulp SK, Chen CS. Retraction of "Development of Novel Adenosine Monophosphate-Activated Protein Kinase Activators". Journal of Medicinal Chemistry. PMID 29772897 DOI: 10.1021/acs.jmedchem.8b00707  0.44
2018 Weng JR, Dokla EME, Bai LY, Chen CS, Chiu SJ, Shieh TM. An AMPK Activator, Compound 59, Induces Autophagy and Apoptosis in Human Oral Squamous Cell Carcinoma. Basic & Clinical Pharmacology & Toxicology. PMID 29394526 DOI: 10.1111/bcpt.12976  0.44
2017 Hsieh HY, Chuang HC, Shen FH, Detroja K, Hsin LW, Chen CS. Targeting breast cancer stem cells by novel HDAC3-selective inhibitors. European Journal of Medicinal Chemistry. 140: 42-51. PMID 28923385 DOI: 10.1016/j.ejmech.2017.08.069  0.44
2017 Murahari S, Jalkanen AL, Kulp SK, Chen CS, Modiano JF, London CA, Kisseberth WC. Sensitivity of osteosarcoma cells to HDAC inhibitor AR-42 mediated apoptosis. Bmc Cancer. 17: 67. PMID 28109246 DOI: 10.1186/s12885-017-3046-6  0.44
2017 Chuang HC, Huang PH, Kulp SK, Chen CS. Pharmacological Strategies to Target Oncogenic KRAS Signaling in Pancreatic Cancer. Pharmacological Research. PMID 28077300 DOI: 10.1016/j.phrs.2017.01.006  0.44
2016 Chu PC, Kulp SK, Bekaii-Saab T, Chen CS. Targeting integrin-linked kinase to suppress oncogenic KRAS signaling in pancreatic cancer. Small Gtpases. 1-5. PMID 27936345 DOI: 10.1080/21541248.2016.1251383  0.44
2016 Henderson SE, Ding LY, Mo X, Bekaii-Saab T, Kulp SK, Chen CS, Huang PH. Suppression of Tumor Growth and Muscle Wasting in a Transgenic Mouse Model of Pancreatic Cancer by the Novel Histone Deacetylase Inhibitor AR-42. Neoplasia (New York, N.Y.). 18: 765-774. PMID 27889645 DOI: 10.1016/j.neo.2016.10.003  0.44
2016 Trikha P, Plews RL, Stiff A, Gautam S, Hsu V, Abood D, Wesolowski R, Landi I, Mo X, Phay J, Chen CS, Byrd J, Caligiuri M, Tridandapani S, Carson W. Targeting myeloid-derived suppressor cells using a novel adenosine monophosphate-activated protein kinase (AMPK) activator. Oncoimmunology. 5: e1214787. PMID 27757311 DOI: 10.1080/2162402X.2016.1214787  0.44
2016 Himmel LE, Lustberg MB, DeVries AC, Poi M, Chen CS, Kulp SK. Minocycline, a putative neuroprotectant, co-administered with doxorubicin-cyclophosphamide chemotherapy in a xenograft model of triple-negative breast cancer. Experimental and Toxicologic Pathology : Official Journal of the Gesellschaft Fur Toxikologische Pathologie. PMID 27555377 DOI: 10.1016/j.etp.2016.08.001  0.44
2016 Hsu EC, Kulp SK, Huang HL, Tu HJ, Chao MW, Tseng YC, Yang MC, Salunke SB, Sullivan NJ, Chen WC, Zhang J, Teng CM, Fu WM, Sun D, Wicha MS, ... ... Chen CS, et al. Integrin-linked kinase as a novel molecular switch of the IL-6-NF-κB signaling loop in breast cancer. Carcinogenesis. PMID 26905583 DOI: 10.1093/carcin/bgw020  0.44
2016 Booth L, Shuch B, Albers T, Roberts JL, Tavallai M, Proniuk S, Zukiwski A, Wang D, Chen CS, Bottaro D, Ecroyd H, Lebedyeva IO, Dent P. Multi-kinase inhibitors can associate with heat shock proteins through their NH2-termini by which they suppress chaperone function. Oncotarget. PMID 26887051 DOI: 10.18632/oncotarget.7349  0.44
2015 Chao MW, Chu PC, Chuang HC, Shen FH, Chou CC, Hsu EC, Himmel LE, Huang HL, Tu HJ, Kulp SK, Teng CM, Chen CS. Non-epigenetic function of HDAC8 in regulating breast cancer stem cells by maintaining Notch1 protein stability. Oncotarget. PMID 26625202 DOI: 10.18632/oncotarget.6427  0.44
2015 Chen WC, Chang YS, Hsu HP, Yen MC, Huang HL, Cho CY, Wang CY, Weng TY, Lai PT, Chen CS, Lin YJ, Lai MD. Therapeutics targeting CD90-integrin-AMPK-CD133 signal axis in liver cancer. Oncotarget. PMID 26556861 DOI: 10.18632/oncotarget.5976  0.44
2015 Burnett JP, Korkaya H, Ouzounova MD, Jiang H, Conley SJ, Newman BW, Sun L, Connarn JN, Chen CS, Zhang N, Wicha MS, Sun D. Trastuzumab resistance induces EMT to transform HER2(+) PTEN(-) to a triple negative breast cancer that requires unique treatment options. Scientific Reports. 5: 15821. PMID 26522776 DOI: 10.1038/srep15821  0.44
2015 Tseng YC, Kulp SK, Lai IL, Hsu EC, He WA, Frankhouser DE, Yan PS, Mo X, Bloomston M, Lesinski GB, Marcucci G, Guttridge DC, Bekaii-Saab T, Chen CS. Preclinical Investigation of the Novel Histone Deacetylase Inhibitor AR-42 in the Treatment of Cancer-Induced Cachexia. Journal of the National Cancer Institute. 107. PMID 26464423 DOI: 10.1093/jnci/djv274  0.44
2015 Dokla EM, Fang CS, Lai PT, Kulp SK, Serya RA, Ismail NS, Abouzid KA, Chen CS. Development of Potent Adenosine Monophosphate Activated Protein Kinase (AMPK) Activators. Chemmedchem. PMID 26350292 DOI: 10.1002/cmdc.201500371  0.44
2015 Tsai YT, Lozanski G, Lehman A, Sass EJ, Hertlein E, Salunke SB, Chen CS, Grever MR, Byrd JC, Lucas DM. BRAF(V600E) induces ABCB1/P-glycoprotein expression and drug resistance in B-cells via AP-1 activation. Leukemia Research. PMID 26350141 DOI: 10.1016/j.leukres.2015.08.017  0.44
2015 Chou YW, Lin FF, Muniyan S, Lin FC, Chen CS, Wang J, Huang CC, Lin MF. Cellular prostatic acid phosphatase (cPAcP) serves as a useful biomarker of histone deacetylase (HDAC) inhibitors in prostate cancer cell growth suppression. Cell & Bioscience. 5: 38. PMID 26185616 DOI: 10.1186/s13578-015-0033-y  0.44
2015 Hsu EC, Kulp SK, Huang HL, Tu HJ, Salunke SB, Sullivan NJ, Sun D, Wicha MS, Shapiro CL, Chen CS. Function of Integrin-Linked Kinase in Modulating the Stemness of IL-6-Abundant Breast Cancer Cells by Regulating γ-Secretase-Mediated Notch1 Activation in Caveolae. Neoplasia (New York, N.Y.). 17: 497-508. PMID 26152358 DOI: 10.1016/j.neo.2015.06.001  0.44
2015 Chatterjee M, Ben-Josef E, Thomas DG, Morgan MA, Zalupski MM, Khan G, Andrew Robinson C, Griffith KA, Chen CS, Ludwig T, Bekaii-Saab T, Chakravarti A, Williams TM. Caveolin-1 is Associated with Tumor Progression and Confers a Multi-Modality Resistance Phenotype in Pancreatic Cancer. Scientific Reports. 5: 10867. PMID 26065715 DOI: 10.1038/srep10867  0.44
2015 Mani R, Chiang CL, Frissora FW, Yan R, Mo X, Baskar S, Rader C, Klisovic R, Phelps MA, Chen CS, Lee RJ, Byrd JC, Baiocchi R, Lee LJ, Muthusamy N. ROR1-targeted delivery of OSU-2S, a nonimmunosuppressive FTY720 derivative, exerts potent cytotoxicity in mantle-cell lymphoma in vitro and in vivo. Experimental Hematology. PMID 25937048 DOI: 10.1016/j.exphem.2015.04.008  0.44
2015 Chou CC, Chuang HC, Salunke SB, Kulp SK, Chen CS. A novel HIF-1α-integrin-linked kinase regulatory loop that facilitates hypoxia-induced HIF-1α expression and epithelial-mesenchymal transition in cancer cells. Oncotarget. 6: 8271-85. PMID 25821081  0.44
2015 Salunke SB, Azad AK, Kapuriya NP, Balada-Llasat JM, Pancholi P, Schlesinger LS, Chen CS. Design and synthesis of novel anti-tuberculosis agents from the celecoxib pharmacophore. Bioorganic & Medicinal Chemistry. 23: 1935-43. PMID 25818768 DOI: 10.1016/j.bmc.2015.03.041  0.44
2015 Yan R, Chuang HC, Kapuriya N, Chou CC, Lai PT, Chang HW, Yang CN, Kulp SK, Chen CS. Exploitation of the ability of γ-tocopherol to facilitate membrane co-localization of Akt and PHLPP1 to develop PHLPP1-targeted Akt inhibitors. Journal of Medicinal Chemistry. 58: 2290-8. PMID 25689347 DOI: 10.1021/jm501751b  0.44
2015 Liu TM, Ling Y, Woyach JA, Beckwith K, Yeh YY, Hertlein E, Zhang X, Lehman A, Awan F, Jones JA, Andritsos LA, Maddocks K, MacMurray J, Salunke SB, Chen CS, et al. OSU-T315: a novel targeted therapeutic that antagonizes AKT membrane localization and activation of chronic lymphocytic leukemia cells. Blood. 125: 284-95. PMID 25293770 DOI: 10.1182/blood-2014-06-583518  0.44
2015 Berman-Booty LD, Thomas-Ahner JM, Bolon B, Oglesbee MJ, Clinton SK, Kulp SK, Chen CS, La Perle KM. Extra-prostatic transgene-associated neoplastic lesions in transgenic adenocarcinoma of the mouse prostate (TRAMP) mice. Toxicologic Pathology. 43: 186-97. PMID 24742627 DOI: 10.1177/0192623314531351  0.44
2014 Lo JH, Kulp SK, Chen CS, Chiu HC. Sensitization of intracellular Salmonella enterica serovar Typhimurium to aminoglycosides in vitro and in vivo by a host-targeted antimicrobial agent. Antimicrobial Agents and Chemotherapy. 58: 7375-82. PMID 25267669 DOI: 10.1128/AAC.03778-14  0.44
2014 El-Gamal D, Williams K, LaFollette TD, Cannon M, Blachly JS, Zhong Y, Woyach JA, Williams E, Awan FT, Jones J, Andritsos L, Maddocks K, Wu CH, Chen CS, Lehman A, et al. PKC-β as a therapeutic target in CLL: PKC inhibitor AEB071 demonstrates preclinical activity in CLL. Blood. 124: 1481-91. PMID 25001469 DOI: 10.1182/blood-2014-05-574830  0.44
2014 Chou CC, Lee KH, Lai IL, Wang D, Mo X, Kulp SK, Shapiro CL, Chen CS. AMPK reverses the mesenchymal phenotype of cancer cells by targeting the Akt-MDM2-Foxo3a signaling axis. Cancer Research. 74: 4783-95. PMID 24994714 DOI: 10.1158/0008-5472.CAN-14-0135  0.44
2014 Mao Y, Wang J, Zhao Y, Yan R, Li H, Chen CS, Lee RJ, Byrd JC, Lee LJ, Muthusamy N, Phelps MA. Quantification of OSU-2S, a novel derivative of FTY720, in mouse plasma by liquid chromatography-tandem mass spectrometry. Journal of Pharmaceutical and Biomedical Analysis. 98: 160-5. PMID 24927402 DOI: 10.1016/j.jpba.2014.05.022  0.44
2014 Lai IL, Chou CC, Lai PT, Fang CS, Shirley LA, Yan R, Mo X, Bloomston M, Kulp SK, Bekaii-Saab T, Chen CS. Targeting the Warburg effect with a novel glucose transporter inhibitor to overcome gemcitabine resistance in pancreatic cancer cells. Carcinogenesis. 35: 2203-13. PMID 24879635 DOI: 10.1093/carcin/bgu124  0.44
2014 Liu FL, Hsu JL, Lee YJ, Dong YS, Kung FL, Chen CS, Guh JH. Calanquinone A induces anti-glioblastoma activity through glutathione-involved DNA damage and AMPK activation. European Journal of Pharmacology. 730: 90-101. PMID 24607408 DOI: 10.1016/j.ejphar.2014.02.029  0.44
2014 Chen CH, Chen MC, Wang JC, Tsai AC, Chen CS, Liou JP, Pan SL, Teng CM. Synergistic interaction between the HDAC inhibitor, MPT0E028, and sorafenib in liver cancer cells in vitro and in vivo. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 20: 1274-87. PMID 24520095 DOI: 10.1158/1078-0432.CCR-12-3909  0.44
2014 Hensley PJ, Desiniotis A, Wang C, Stromberg A, Chen CS, Kyprianou N. Novel pharmacologic targeting of tight junctions and focal adhesions in prostate cancer cells. Plos One. 9: e86238. PMID 24497940 DOI: 10.1371/journal.pone.0086238  0.44
2014 Chou CC, Salunke SB, Kulp SK, Chen CS. Prospects on strategies for therapeutically targeting oncogenic regulatory factors by small-molecule agents. Journal of Cellular Biochemistry. 115: 611-24. PMID 24166934 DOI: 10.1002/jcb.24704  0.44
2014 Jiang Y, Wang J, Rozewski DM, Kolli S, Wu CH, Chen CS, Yang X, Hofmeister CC, Byrd JC, Johnson AJ, Phelps MA. Sensitive liquid chromatography/mass spectrometry methods for quantification of pomalidomide in mouse plasma and brain tissue. Journal of Pharmaceutical and Biomedical Analysis. 88: 262-8. PMID 24095801 DOI: 10.1016/j.jpba.2013.08.036  0.44
2014 Mao Y, Wang J, Zhao Y, Wu Y, Kwak KJ, Chen CS, Byrd JC, Lee RJ, Phelps MA, Lee LJ, Muthusamy N. A novel liposomal formulation of FTY720 (fingolimod) for promising enhanced targeted delivery. Nanomedicine : Nanotechnology, Biology, and Medicine. 10: 393-400. PMID 23969101 DOI: 10.1016/j.nano.2013.08.001  0.44
2014 Chuang HC, Chou CC, Kulp SK, Chen CS. AMPK as a potential anticancer target - friend or foe? Current Pharmaceutical Design. 20: 2607-18. PMID 23859619  0.44
2013 Neviani P, Harb JG, Oaks JJ, Santhanam R, Walker CJ, Ellis JJ, Ferenchak G, Dorrance AM, Paisie CA, Eiring AM, Ma Y, Mao HC, Zhang B, Wunderlich M, May PC, ... ... Chen CS, et al. PP2A-activating drugs selectively eradicate TKI-resistant chronic myeloid leukemic stem cells. The Journal of Clinical Investigation. 123: 4144-57. PMID 23999433 DOI: 10.1172/JCI68951  0.44
2013 Chu PC, Kulp SK, Chen CS. Insulin-like growth factor-I receptor is suppressed through transcriptional repression and mRNA destabilization by a novel energy restriction-mimetic agent. Carcinogenesis. 34: 2694-705. PMID 23864387 DOI: 10.1093/carcin/bgt251  0.44
2013 Lee SL, Chou CC, Chuang HC, Hsu EC, Chiu PC, Kulp SK, Byrd JC, Chen CS. Functional Role of mTORC2 versus Integrin-Linked Kinase in Mediating Ser473-Akt Phosphorylation in PTEN-Negative Prostate and Breast Cancer Cell Lines. Plos One. 8: e67149. PMID 23840605 DOI: 10.1371/journal.pone.0067149  0.44
2013 Lee SY, Huang Z, Kang TH, Soong RS, Knoff J, Axenfeld E, Wang C, Alvarez RD, Chen CS, Hung CF, Wu TC. Histone deacetylase inhibitor AR-42 enhances E7-specific CD8⁺ T cell-mediated antitumor immunity induced by therapeutic HPV DNA vaccination. Journal of Molecular Medicine (Berlin, Germany). 91: 1221-31. PMID 23715898 DOI: 10.1007/s00109-013-1054-9  0.44
2013 Yang YL, Huang PH, Chiu HC, Kulp SK, Chen CS, Kuo CJ, Chen HD, Chen CS. Histone deacetylase inhibitor AR42 regulates telomerase activity in human glioma cells via an Akt-dependent mechanism. Biochemical and Biophysical Research Communications. 435: 107-12. PMID 23624506 DOI: 10.1016/j.bbrc.2013.04.049  0.44
2013 Huang PH, Chuang HC, Chou CC, Wang H, Lee SL, Yang HC, Chiu HC, Kapuriya N, Wang D, Kulp SK, Chen CS. Vitamin E facilitates the inactivation of the kinase Akt by the phosphatase PHLPP1. Science Signaling. 6: ra19. PMID 23512990 DOI: 10.1126/scisignal.2003816  0.44
2013 Berman-Booty LD, Chu PC, Thomas-Ahner JM, Bolon B, Wang D, Yang T, Clinton SK, Kulp SK, Chen CS. Suppression of prostate epithelial proliferation and intraprostatic progrowth signaling in transgenic mice by a new energy restriction-mimetic agent. Cancer Prevention Research (Philadelphia, Pa.). 6: 232-41. PMID 23275006 DOI: 10.1158/1940-6207.CAPR-12-0057  0.44
2013 Burns SS, Akhmametyeva EM, Oblinger JL, Bush ML, Huang J, Senner V, Chen CS, Jacob A, Welling DB, Chang LS. Histone deacetylase inhibitor AR-42 differentially affects cell-cycle transit in meningeal and meningioma cells, potently inhibiting NF2-deficient meningioma growth. Cancer Research. 73: 792-803. PMID 23151902 DOI: 10.1158/0008-5472.CAN-12-1888  0.44
2012 Chu PC, Chuang HC, Kulp SK, Chen CS. The mRNA-stabilizing factor HuR protein is targeted by β-TrCP protein for degradation in response to glycolysis inhibition. The Journal of Biological Chemistry. 287: 43639-50. PMID 23115237 DOI: 10.1074/jbc.M112.393678  0.44
2012 Wei S, Chu PC, Chuang HC, Hung WC, Kulp SK, Chen CS. Targeting the oncogenic E3 ligase Skp2 in prostate and breast cancer cells with a novel energy restriction-mimetic agent. Plos One. 7: e47298. PMID 23071779 DOI: 10.1371/journal.pone.0047298  0.44
2012 Chiu HC, Lee SL, Kapuriya N, Wang D, Chen YR, Yu SL, Kulp SK, Teng LJ, Chen CS. Development of novel antibacterial agents against methicillin-resistant Staphylococcus aureus. Bioorganic & Medicinal Chemistry. 20: 4653-60. PMID 22750009 DOI: 10.1016/j.bmc.2012.06.018  0.44
2012 Chuang HC, Kapuriya N, Kulp SK, Chen CS, Shapiro CL. Differential anti-proliferative activities of poly(ADP-ribose) polymerase (PARP) inhibitors in triple-negative breast cancer cells. Breast Cancer Research and Treatment. 134: 649-59. PMID 22678161 DOI: 10.1007/s10549-012-2106-5  0.44
2012 Lapalombella R, Yeh YY, Wang L, Ramanunni A, Rafiq S, Jha S, Staubli J, Lucas DM, Mani R, Herman SE, Johnson AJ, Lozanski A, Andritsos L, Jones J, Flynn JM, ... ... Chen CS, et al. Tetraspanin CD37 directly mediates transduction of survival and apoptotic signals. Cancer Cell. 21: 694-708. PMID 22624718 DOI: 10.1016/j.ccr.2012.03.040  0.44
2012 Hsu JL, Ho YF, Li TK, Chen CS, Hsu LC, Guh JH. Rottlerin potentiates camptothecin-induced cytotoxicity in human hormone refractory prostate cancers through increased formation and stabilization of topoisomerase I-DNA cleavage complexes in a PKCδ-independent pathway. Biochemical Pharmacology. 84: 59-67. PMID 22490701 DOI: 10.1016/j.bcp.2012.03.023  0.44
2012 Wang D, Chu PC, Yang CN, Yan R, Chuang YC, Kulp SK, Chen CS. Development of a novel class of glucose transporter inhibitors. Journal of Medicinal Chemistry. 55: 3827-36. PMID 22468970 DOI: 10.1021/jm300015m  0.44
2012 Booth L, Cazanave SC, Hamed HA, Yacoub A, Ogretmen B, Chen CS, Grant S, Dent P. OSU-03012 suppresses GRP78/BiP expression that causes PERK-dependent increases in tumor cell killing. Cancer Biology & Therapy. 13: 224-36. PMID 22354011 DOI: 10.4161/cbt.13.4.18877  0.44
2012 Hsu JL, Leong PK, Ho YF, Hsu LC, Lu PH, Chen CS, Guh JH. Pim-1 knockdown potentiates paclitaxel-induced apoptosis in human hormone-refractory prostate cancers through inhibition of NHEJ DNA repair. Cancer Letters. 319: 214-22. PMID 22261337 DOI: 10.1016/j.canlet.2012.01.004  0.44
2012 Jacob A, Oblinger J, Bush ML, Brendel V, Santarelli G, Chaudhury AR, Kulp S, La Perle KM, Chen CS, Chang LS, Welling DB. Preclinical validation of AR42, a novel histone deacetylase inhibitor, as treatment for vestibular schwannomas. The Laryngoscope. 122: 174-89. PMID 22109824 DOI: 10.1002/lary.22392  0.44
2012 Berman-Booty LD, Sargeant AM, Rosol TJ, Rengel RC, Clinton SK, Chen CS, Kulp SK. A review of the existing grading schemes and a proposal for a modified grading scheme for prostatic lesions in TRAMP mice. Toxicologic Pathology. 40: 5-17. PMID 22021166 DOI: 10.1177/0192623311425062  0.44
2011 Alinari L, Mahoney E, Patton J, Zhang X, Huynh L, Earl CT, Mani R, Mao Y, Yu B, Quinion C, Towns WH, Chen CS, Goldenberg DM, Blum KA, Byrd JC, et al. FTY720 increases CD74 expression and sensitizes mantle cell lymphoma cells to milatuzumab-mediated cell death. Blood. 118: 6893-903. PMID 22042694 DOI: 10.1182/blood-2011-06-363879  0.44
2011 Lee KH, Hsu EC, Guh JH, Yang HC, Wang D, Kulp SK, Shapiro CL, Chen CS. Targeting energy metabolic and oncogenic signaling pathways in triple-negative breast cancer by a novel adenosine monophosphate-activated protein kinase (AMPK) activator. The Journal of Biological Chemistry. 286: 39247-58. PMID 21917926 DOI: 10.1074/jbc.M111.264598  0.44
2011 Hofmeister CC, Yang X, Pichiorri F, Chen P, Rozewski DM, Johnson AJ, Lee S, Liu Z, Garr CL, Hade EM, Ji J, Schaaf LJ, Benson DM, Kraut EH, Hicks WJ, ... ... Chen CS, et al. Phase I trial of lenalidomide and CCI-779 in patients with relapsed multiple myeloma: evidence for lenalidomide-CCI-779 interaction via P-glycoprotein. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 3427-34. PMID 21825263 DOI: 10.1200/JCO.2010.32.4962  0.44
2011 Lee SL, Hsu EC, Chou CC, Chuang HC, Bai LY, Kulp SK, Chen CS. Identification and characterization of a novel integrin-linked kinase inhibitor. Journal of Medicinal Chemistry. 54: 6364-74. PMID 21823616 DOI: 10.1021/jm2007744  0.44
2011 Zimmerman B, Sargeant A, Landes K, Fernandez SA, Chen CS, Lairmore MD. Efficacy of novel histone deacetylase inhibitor, AR42, in a mouse model of, human T-lymphotropic virus type 1 adult T cell lymphoma. Leukemia Research. 35: 1491-7. PMID 21802726 DOI: 10.1016/j.leukres.2011.07.015  0.44
2011 Bush ML, Oblinger J, Brendel V, Santarelli G, Huang J, Akhmametyeva EM, Burns SS, Wheeler J, Davis J, Yates CW, Chaudhury AR, Kulp S, Chen CS, Chang LS, Welling DB, et al. AR42, a novel histone deacetylase inhibitor, as a potential therapy for vestibular schwannomas and meningiomas. Neuro-Oncology. 13: 983-99. PMID 21778190 DOI: 10.1093/neuonc/nor072  0.44
2011 Bai LY, Ma Y, Kulp SK, Wang SH, Chiu CF, Frissora F, Mani R, Mo X, Jarjoura D, Byrd JC, Chen CS, Muthusamy N. OSU-DY7, a novel D-tyrosinol derivative, mediates cytotoxicity in chronic lymphocytic leukaemia and Burkitt lymphoma through p38 mitogen-activated protein kinase pathway. British Journal of Haematology. 153: 623-33. PMID 21470196 DOI: 10.1111/j.1365-2141.2010.08443.x  0.44
2011 Omar HA, Chou CC, Berman-Booty LD, Ma Y, Hung JH, Wang D, Kogure T, Patel T, Terracciano L, Muthusamy N, Byrd JC, Kulp SK, Chen CS. Antitumor effects of OSU-2S, a nonimmunosuppressive analogue of FTY720, in hepatocellular carcinoma. Hepatology (Baltimore, Md.). 53: 1943-58. PMID 21391227 DOI: 10.1002/hep.24293  0.44
2011 Ching TT, Chiang WC, Chen CS, Hsu AL. Celecoxib extends C. elegans lifespan via inhibition of insulin-like signaling but not cyclooxygenase-2 activity. Aging Cell. 10: 506-19. PMID 21348927 DOI: 10.1111/j.1474-9726.2011.00688.x  0.68
2011 Thudi NK, Shu ST, Martin CK, Lanigan LG, Nadella MV, Van Bokhoven A, Werbeck JL, Simmons JK, Murahari S, Kisseberth WC, Breen M, Williams C, Chen CS, McCauley LK, Keller ET, et al. Development of a brain metastatic canine prostate cancer cell line. The Prostate. 71: 1251-63. PMID 21321976 DOI: 10.1002/pros.21341  0.44
2011 Chen CH, Huang PH, Chu PC, Chen MC, Chou CC, Wang D, Kulp SK, Teng CM, Wang Q, Chen CS. Energy restriction-mimetic agents induce apoptosis in prostate cancer cells in part through epigenetic activation of KLF6 tumor suppressor gene expression. The Journal of Biological Chemistry. 286: 9968-76. PMID 21282102 DOI: 10.1074/jbc.M110.203240  0.44
2011 Chen MC, Chen CH, Chuang HC, Kulp SK, Teng CM, Chen CS. Novel mechanism by which histone deacetylase inhibitors facilitate topoisomerase IIα degradation in hepatocellular carcinoma cells. Hepatology (Baltimore, Md.). 53: 148-59. PMID 21254166 DOI: 10.1002/hep.23964  0.44
2011 Wang B, Huang PH, Chen CS, Forsyth CJ. Total syntheses of the histone deacetylase inhibitors largazole and 2-epi-largazole: application of N-heterocyclic carbene mediated acylations in complex molecule synthesis. The Journal of Organic Chemistry. 76: 1140-50. PMID 21244075 DOI: 10.1021/jo102478x  0.44
2011 Huang PH, Chen CH, Chou CC, Sargeant AM, Kulp SK, Teng CM, Byrd JC, Chen CS. Histone deacetylase inhibitors stimulate histone H3 lysine 4 methylation in part via transcriptional repression of histone H3 lysine 4 demethylases. Molecular Pharmacology. 79: 197-206. PMID 20959362 DOI: 10.1124/mol.110.067702  0.44
2010 Omar HA, Berman-Booty L, Kulp SK, Chen CS. Energy restriction as an antitumor target. Future Oncology (London, England). 6: 1675-9. PMID 21142654 DOI: 10.2217/fon.10.130  0.44
2010 Chandler HL, Webb TR, Barden CA, Thangavelu M, Kulp SK, Chen CS, Colitz CM. The effect of phosphorylated Akt inhibition on posterior capsule opacification in an ex vivo canine model. Molecular Vision. 16: 2202-14. PMID 21139685  0.44
2010 Lucas DM, Alinari L, West DA, Davis ME, Edwards RB, Johnson AJ, Blum KA, Hofmeister CC, Freitas MA, Parthun MR, Wang D, Lehman A, Zhang X, Jarjoura D, Kulp SK, ... ... Chen CS, et al. The novel deacetylase inhibitor AR-42 demonstrates pre-clinical activity in B-cell malignancies in vitro and in vivo. Plos One. 5: e10941. PMID 20532179 DOI: 10.1371/journal.pone.0010941  0.68
2010 Liu Q, Alinari L, Chen CS, Yan F, Dalton JT, Lapalombella R, Zhang X, Mani R, Lin T, Byrd JC, Baiocchi RA, Muthusamy N. FTY720 shows promising in vitro and in vivo preclinical activity by downmodulating Cyclin D1 and phospho-Akt in mantle cell lymphoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 16: 3182-92. PMID 20460491 DOI: 10.1158/1078-0432.CCR-09-2484  0.44
2010 Weng JR, Omar HA, Kulp SK, Chen CS. Pharmacological exploitation of indole-3-carbinol to develop potent antitumor agents. Mini Reviews in Medicinal Chemistry. 10: 398-404. PMID 20370707  0.44
2010 Lin TY, Fenger J, Murahari S, Bear MD, Kulp SK, Wang D, Chen CS, Kisseberth WC, London CA. AR-42, a novel HDAC inhibitor, exhibits biologic activity against malignant mast cell lines via down-regulation of constitutively activated Kit. Blood. 115: 4217-25. PMID 20233974 DOI: 10.1182/blood-2009-07-231985  0.44
2010 Guh JH, Chang WL, Yang J, Lee SL, Wei S, Wang D, Kulp SK, Chen CS. Development of novel adenosine monophosphate-activated protein kinase activators. Journal of Medicinal Chemistry. 53: 2552-61. PMID 20170185 DOI: 10.1021/jm901773d  0.44
2010 Hamed HA, Yacoub A, Park MA, Eulitt P, Sarkar D, Dimitrie IP, Chen CS, Grant S, Curiel DT, Fisher PB, Dent P. OSU-03012 enhances Ad.7-induced GBM cell killing via ER stress and autophagy and by decreasing expression of mitochondrial protective proteins. Cancer Biology & Therapy. 9: 526-36. PMID 20107314  0.44
2010 Wei S, Kulp SK, Chen CS. Energy restriction as an antitumor target of thiazolidinediones. The Journal of Biological Chemistry. 285: 9780-91. PMID 20093366 DOI: 10.1074/jbc.M109.065466  0.44
2010 Lapalombella R, Andritsos L, Liu Q, May SE, Browning R, Pham LV, Blum KA, Blum W, Ramanunni A, Raymond CA, Smith LL, Lehman A, Mo X, Jarjoura D, Chen CS, et al. Lenalidomide treatment promotes CD154 expression on CLL cells and enhances production of antibodies by normal B cells through a PI3-kinase-dependent pathway. Blood. 115: 2619-29. PMID 19965642 DOI: 10.1182/blood-2009-09-242438  0.44
2009 Chiu HC, Soni S, Kulp SK, Curry H, Wang D, Gunn JS, Schlesinger LS, Chen CS. Eradication of intracellular Francisella tularensis in THP-1 human macrophages with a novel autophagy inducing agent. Journal of Biomedical Science. 16: 110. PMID 20003180 DOI: 10.1186/1423-0127-16-110  0.44
2009 Chiu HC, Kulp SK, Soni S, Wang D, Gunn JS, Schlesinger LS, Chen CS. Eradication of intracellular Salmonella enterica serovar Typhimurium with a small-molecule, host cell-directed agent. Antimicrobial Agents and Chemotherapy. 53: 5236-44. PMID 19805568 DOI: 10.1128/AAC.00555-09  0.44
2009 Wang D, Chuang HC, Weng SC, Huang PH, Hsieh HY, Kulp SK, Chen CS. alpha-Tocopheryl succinate as a scaffold to develop potent inhibitors of breast cancer cell adhesion. Journal of Medicinal Chemistry. 52: 5642-8. PMID 19708661 DOI: 10.1021/jm9002457  0.44
2009 Omar HA, Sargeant AM, Weng JR, Wang D, Kulp SK, Patel T, Chen CS. Targeting of the Akt-nuclear factor-kappa B signaling network by [1-(4-chloro-3-nitrobenzenesulfonyl)-1H-indol-3-yl]-methanol (OSU-A9), a novel indole-3-carbinol derivative, in a mouse model of hepatocellular carcinoma. Molecular Pharmacology. 76: 957-68. PMID 19706731 DOI: 10.1124/mol.109.058180  0.44
2009 Weng JR, Tsai CH, Omar HA, Sargeant AM, Wang D, Kulp SK, Shapiro CL, Chen CS. OSU-A9, a potent indole-3-carbinol derivative, suppresses breast tumor growth by targeting the Akt-NF-kappaB pathway and stress response signaling. Carcinogenesis. 30: 1702-9. PMID 19706645 DOI: 10.1093/carcin/bgp202  0.44
2009 Yang YT, Balch C, Kulp SK, Mand MR, Nephew KP, Chen CS. A rationally designed histone deacetylase inhibitor with distinct antitumor activity against ovarian cancer. Neoplasia (New York, N.Y.). 11: 552-63, 3 p followin. PMID 19484144  0.44
2009 Huang PH, Wang D, Chuang HC, Wei S, Kulp SK, Chen CS. alpha-Tocopheryl succinate and derivatives mediate the transcriptional repression of androgen receptor in prostate cancer cells by targeting the PP2A-JNK-Sp1-signaling axis. Carcinogenesis. 30: 1125-31. PMID 19420015 DOI: 10.1093/carcin/bgp112  0.44
2009 Chiu HC, Yang J, Soni S, Kulp SK, Gunn JS, Schlesinger LS, Chen CS. Pharmacological exploitation of an off-target antibacterial effect of the cyclooxygenase-2 inhibitor celecoxib against Francisella tularensis. Antimicrobial Agents and Chemotherapy. 53: 2998-3002. PMID 19398640 DOI: 10.1128/AAC.00048-09  0.44
2009 Wei S, Chuang HC, Tsai WC, Yang HC, Ho SR, Paterson AJ, Kulp SK, Chen CS. Thiazolidinediones mimic glucose starvation in facilitating Sp1 degradation through the up-regulation of beta-transducin repeat-containing protein. Molecular Pharmacology. 76: 47-57. PMID 19372209 DOI: 10.1124/mol.109.055376  0.44
2009 Lee TX, Packer MD, Huang J, Akhmametyeva EM, Kulp SK, Chen CS, Giovannini M, Jacob A, Welling DB, Chang LS. Growth inhibitory and anti-tumour activities of OSU-03012, a novel PDK-1 inhibitor, on vestibular schwannoma and malignant schwannoma cells. European Journal of Cancer (Oxford, England : 1990). 45: 1709-20. PMID 19359162 DOI: 10.1016/j.ejca.2009.03.013  0.44
2002 Zhu J, Song X, Lin HP, Young DC, Yan S, Marquez VE, Chen CS. Using cyclooxygenase-2 inhibitors as molecular platforms to develop a new class of apoptosis-inducing agents. Journal of the National Cancer Institute. 94: 1745-57. PMID 12464646  0.4
2002 Johnson AJ, Hsu AL, Lin HP, Song X, Chen CS. The cyclo-oxygenase-2 inhibitor celecoxib perturbs intracellular calcium by inhibiting endoplasmic reticulum Ca2+-ATPases: a plausible link with its anti-tumour effect and cardiovascular risks. The Biochemical Journal. 366: 831-7. PMID 12076251 DOI: 10.1042/BJ20020279  0.68
2002 Song X, Lin HP, Johnson AJ, Tseng PH, Yang YT, Kulp SK, Chen CS. Cyclooxygenase-2, player or spectator in cyclooxygenase-2 inhibitor-induced apoptosis in prostate cancer cells. Journal of the National Cancer Institute. 94: 585-91. PMID 11959891  0.68
2001 Ching TT, Lin HP, Yang CC, Oliveira M, Lu PJ, Chen CS. Specific binding of the C-terminal Src homology 2 domain of the p85alpha subunit of phosphoinositide 3-kinase to phosphatidylinositol 3,4,5-trisphosphate. Localization and engineering of the phosphoinositide-binding motif. The Journal of Biological Chemistry. 276: 43932-8. PMID 11555646 DOI: 10.1074/jbc.M105159200  0.68
2001 Ching TT, Hsu AL, Johnson AJ, Chen CS. Phosphoinositide 3-kinase facilitates antigen-stimulated Ca(2+) influx in RBL-2H3 mast cells via a phosphatidylinositol 3,4,5-trisphosphate-sensitive Ca(2+) entry mechanism. The Journal of Biological Chemistry. 276: 14814-20. PMID 11278575 DOI: 10.1074/jbc.M009851200  0.68
2001 Wang DS, Hsu AL, Chen CS. A phosphatidylinositol 3,4,5-trisphosphate analogue with low serum protein-binding affinity. Bioorganic & Medicinal Chemistry. 9: 133-9. PMID 11197333  0.68
2000 Wang DS, Ching TT, St Pyrek J, Chen CS. Biotinylated phosphatidylinositol 3,4,5-trisphosphate as affinity ligand. Analytical Biochemistry. 280: 301-7. PMID 10790314 DOI: 10.1006/abio.2000.4525  0.68
2000 Hsu AL, Ching TT, Wang DS, Song X, Rangnekar VM, Chen CS. The cyclooxygenase-2 inhibitor celecoxib induces apoptosis by blocking Akt activation in human prostate cancer cells independently of Bcl-2. The Journal of Biological Chemistry. 275: 11397-403. PMID 10753955 DOI: 10.1074/jbc.275.15.11397  0.44
2000 Hsu AL, Ching TT, Sen G, Wang DS, Bondada S, Authi KS, Chen CS. Novel function of phosphoinositide 3-kinase in T cell Ca2+ signaling. A phosphatidylinositol 3,4,5-trisphosphate-mediated Ca2+ entry mechanism. The Journal of Biological Chemistry. 275: 16242-50. PMID 10748064 DOI: 10.1074/jbc.M002077200  0.68
1999 Ching TT, Wang DS, Hsu AL, Lu PJ, Chen CS. Identification of multiple phosphoinositide-specific phospholipases D as new regulatory enzymes for phosphatidylinositol 3,4, 5-trisphosphate. The Journal of Biological Chemistry. 274: 8611-7. PMID 10085097  0.68
1998 Lu PJ, Hsu AL, Wang DS, Chen CS. Phosphatidylinositol 3,4,5-trisphosphate triggers platelet aggregation by activating Ca2+ influx. Biochemistry. 37: 9776-83. PMID 9657691 DOI: 10.1021/bi980163o  0.68
1998 Lu PJ, Hsu AL, Wang DS, Yan HY, Yin HL, Chen CS. Phosphoinositide 3-kinase in rat liver nuclei. Biochemistry. 37: 5738-45. PMID 9548960 DOI: 10.1021/bi972551g  0.68
1998 Hsu AL, Lu PJ, Chen CS. Regulation of nuclear calcium uptake by inositol phosphates and external calcium. Biochemical and Biophysical Research Communications. 243: 653-6. PMID 9500990 DOI: 10.1006/bbrc.1998.8161  0.68
Show low-probability matches.